NCT01214564View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Seborrheic Keratosis
Interventions
DRUG

PEP005 (ingenol mebutate) Gel

0.05%

Trial Locations (2)

2217

Southderm Pty Ltd, Kogarah

4102

Specialist Connect, Woolloongabba

Sponsors

Lead Sponsor

Peplin
All Listed Sponsors
lead

Peplin

INDUSTRY

NCT01214564 - Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis | Biotech Hunter | Biotech Hunter